NCT03166085: PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer

NCT03166085
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Symptomatic brain or CNS metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03166085

Comments are closed.

Up ↑